Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $ELVN vs $EWTX | Chartloom

Compare

$ELVN vs $EWTX

Enliven Therapeutics Inc · Edgewise Therapeutics Inc

ELVN

Enliven Therapeutics Inc

EWTX

Edgewise Therapeutics Inc

Compare $ELVN vs $EWTX

Comparing Enliven Therapeutics Inc and Edgewise Therapeutics Inc

ELVNEnliven Therapeutics Inc

EWTXEdgewise Therapeutics Inc

ELVNEnliven Therapeutics Inc

Market cap

$2.76B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

154.1%

52W performance

89.7%

FCF yield

-2.4%

EWTXEdgewise Therapeutics Inc

Market cap

$3.90B

P/E (TTM)

—

Forward P/E (NTM)

19.86x

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

52.8%

52W performance

140.1%

FCF yield

-4.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ELVN

EWTX

Detailed metrics comparison

ELVN

Enliven Therapeutics Inc

EWTX

Edgewise Therapeutics Inc

Market Cap

ELVN$2.76B

EWTX$3.90B

Enterprise Value

ELVN$2.62B

EWTX$3.83B

Price

ELVN$39.49

EWTX$36.28

P/E Ratio

ELVNN/A

EWTXN/A

P/S Ratio

ELVN0.00x

EWTX0.00x

EV/Sales

ELVN0.00x

EWTX0.00x

EV/EBITDA

ELVN770.73x

EWTX0.00x

P/B Ratio

ELVN3.35x

EWTX9.47x

P/FCF Ratio

ELVNN/A

EWTXN/A

EV/FCF

ELVN-39.11x

EWTX-24.12x

PEG Ratio

ELVNN/A

EWTXN/A

Forward P/E (NTM)

ELVNN/A

EWTX19.86x

Forward P/S (NTM)

ELVNN/A

EWTXN/A

Revenue (TTM)

ELVN$0

EWTX$0

Revenue Growth (YoY)

ELVNN/A

EWTXN/A

Forward Rev Growth

ELVN28.4%

EWTX0.0%

Gross Margin (TTM)

ELVN0.0%

EWTX0.0%

Operating Margin (TTM)

ELVN0.0%

EWTX0.0%

EBITDA Margin (TTM)

ELVN0.0%

EWTX0.0%

Net Margin (TTM)

ELVN0.0%

EWTX0.0%

FCF Margin (TTM)

ELVNN/A

EWTXN/A

Net Income (TTM)

ELVN$-106M

EWTX$-197M

FCF (TTM)

ELVN$-67M

EWTX$-159M

EPS (TTM)

ELVN-$1.60

EWTX-$1.83

ROE (TTM)

ELVN-1855.0%

EWTX-3901.0%

ROA (TTM)

ELVN-1809.0%

EWTX-3696.0%

ROIC (TTM)

ELVN-1855.0%

EWTX-3901.0%

Cash

ELVN$136M

EWTX$72M

Debt

ELVN$0

EWTX$0

Net Cash/Debt

ELVN$136M

EWTX$72M

Current Ratio (TTM)

ELVN64.07x

EWTX16.24x

Quick Ratio (TTM)

ELVN63.21x

EWTX16.01x

Debt/Equity (TTM)

ELVN0.00x

EWTX0.00x

Debt/Assets (TTM)

ELVN0.0%

EWTX0.0%

Interest Coverage (TTM)

ELVNN/A

EWTXN/A

Net Debt/EBITDA (TTM)

ELVN0.00x

EWTX0.00x

Beta

ELVN0.55

EWTX0.37

52W Performance

ELVN89.7%

EWTX140.1%

YTD Performance

ELVN154.1%

EWTX52.8%

% from 52W High

ELVN-36.6%

EWTX-25.2%

% from 52W Low

ELVN167.1%

EWTX154.6%

Asset Turnover (TTM)

ELVN0.00x

EWTX0.00x

FCF Yield (TTM)

ELVN-2.4%

EWTX-4.1%

Earnings Yield (TTM)

ELVN-3.8%

EWTX-5.1%

Dividend Yield (TTM)

ELVNN/A

EWTXN/A

Rule of 40

ELVN0.0

EWTX0.0

EV/GP/RG

ELVNN/A

EWTXN/A

Ticker research

View ELVN research View EWTX research

Metric	ELVN Enliven Therapeutics Inc	EWTX Edgewise Therapeutics Inc
Market & Valuation
Market Cap	$2.76B	$3.90B
Enterprise Value	$2.62B	$3.83B
Price	$39.49	$36.28
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	770.73x	0.00x
P/B Ratio	3.35x	9.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.11x	-24.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	19.86x
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	28.4%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-106M	$-197M
FCF (TTM)	$-67M	$-159M
EPS (TTM)	-$1.60	-$1.83
ROE (TTM)	-1855.0%	-3901.0%
ROA (TTM)	-1809.0%	-3696.0%
ROIC (TTM)	-1855.0%	-3901.0%
Financial Health
Cash	$136M	$72M
Debt	$0	$0
Net Cash/Debt	$136M	$72M
Current Ratio (TTM)	64.07x	16.24x
Quick Ratio (TTM)	63.21x	16.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	0.37
52W Performance	89.7%	140.1%
YTD Performance	154.1%	52.8%
% from 52W High	-36.6%	-25.2%
% from 52W Low	167.1%	154.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-2.4%	-4.1%
Earnings Yield (TTM)	-3.8%	-5.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ELVN research	View EWTX research

Valuation

P/S Ratio

ELVN

0.00x

EWTX

0.00x

EV/FCF

ELVN

-39.11x

EWTX

-24.12x

Growth & revenue

Forward Revenue Growth

ELVN

28.4%

EWTX

0.0%

Profitability & performance

Gross Margin

ELVN

0.0%

EWTX

0.0%

ROE

ELVN

-1855.0%

EWTX

-3901.0%

FCF Yield %

ELVN

-2.4%

EWTX

-4.1%

52-Week Performance

EWTX

140.1%

ELVN

89.7%

Detailed metrics comparison

ELVN

Enliven Therapeutics Inc

EWTX

Edgewise Therapeutics Inc

Market Cap

ELVN$2.76B

EWTX$3.90B

Enterprise Value

ELVN$2.62B

EWTX$3.83B

Price

ELVN$39.49

EWTX$36.28

P/E Ratio

ELVNN/A

EWTXN/A

P/S Ratio

ELVN0.00x

EWTX0.00x

EV/Sales

ELVN0.00x

EWTX0.00x

EV/EBITDA

ELVN770.73x

EWTX0.00x

P/B Ratio

ELVN3.35x

EWTX9.47x

P/FCF Ratio

ELVNN/A

EWTXN/A

EV/FCF

ELVN-39.11x

EWTX-24.12x

PEG Ratio

ELVNN/A

EWTXN/A

Forward P/E (NTM)

ELVNN/A

EWTX19.86x

Forward P/S (NTM)

ELVNN/A

EWTXN/A

Revenue (TTM)

ELVN$0

EWTX$0

Revenue Growth (YoY)

ELVNN/A

EWTXN/A

Forward Rev Growth

ELVN28.4%

EWTX0.0%

Gross Margin (TTM)

ELVN0.0%

EWTX0.0%

Operating Margin (TTM)

ELVN0.0%

EWTX0.0%

EBITDA Margin (TTM)

ELVN0.0%

EWTX0.0%

Net Margin (TTM)

ELVN0.0%

EWTX0.0%

FCF Margin (TTM)

ELVNN/A

EWTXN/A

Net Income (TTM)

ELVN$-106M

EWTX$-197M

FCF (TTM)

ELVN$-67M

EWTX$-159M

EPS (TTM)

ELVN-$1.60

EWTX-$1.83

ROE (TTM)

ELVN-1855.0%

EWTX-3901.0%

ROA (TTM)

ELVN-1809.0%

EWTX-3696.0%

ROIC (TTM)

ELVN-1855.0%

EWTX-3901.0%

Cash

ELVN$136M

EWTX$72M

Debt

ELVN$0

EWTX$0

Net Cash/Debt

ELVN$136M

EWTX$72M

Current Ratio (TTM)

ELVN64.07x

EWTX16.24x

Quick Ratio (TTM)

ELVN63.21x

EWTX16.01x

Debt/Equity (TTM)

ELVN0.00x

EWTX0.00x

Debt/Assets (TTM)

ELVN0.0%

EWTX0.0%

Interest Coverage (TTM)

ELVNN/A

EWTXN/A

Net Debt/EBITDA (TTM)

ELVN0.00x

EWTX0.00x

Beta

ELVN0.55

EWTX0.37

52W Performance

ELVN89.7%

EWTX140.1%

YTD Performance

ELVN154.1%

EWTX52.8%

% from 52W High

ELVN-36.6%

EWTX-25.2%

% from 52W Low

ELVN167.1%

EWTX154.6%

Asset Turnover (TTM)

ELVN0.00x

EWTX0.00x

FCF Yield (TTM)

ELVN-2.4%

EWTX-4.1%

Earnings Yield (TTM)

ELVN-3.8%

EWTX-5.1%

Dividend Yield (TTM)

ELVNN/A

EWTXN/A

Rule of 40

ELVN0.0

EWTX0.0

EV/GP/RG

ELVNN/A

EWTXN/A

Ticker research

View ELVN research View EWTX research

Metric	ELVN Enliven Therapeutics Inc	EWTX Edgewise Therapeutics Inc
Market & Valuation
Market Cap	$2.76B	$3.90B
Enterprise Value	$2.62B	$3.83B
Price	$39.49	$36.28
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	770.73x	0.00x
P/B Ratio	3.35x	9.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.11x	-24.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	19.86x
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	28.4%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-106M	$-197M
FCF (TTM)	$-67M	$-159M
EPS (TTM)	-$1.60	-$1.83
ROE (TTM)	-1855.0%	-3901.0%
ROA (TTM)	-1809.0%	-3696.0%
ROIC (TTM)	-1855.0%	-3901.0%
Financial Health
Cash	$136M	$72M
Debt	$0	$0
Net Cash/Debt	$136M	$72M
Current Ratio (TTM)	64.07x	16.24x
Quick Ratio (TTM)	63.21x	16.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	0.37
52W Performance	89.7%	140.1%
YTD Performance	154.1%	52.8%
% from 52W High	-36.6%	-25.2%
% from 52W Low	167.1%	154.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-2.4%	-4.1%
Earnings Yield (TTM)	-3.8%	-5.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ELVN research	View EWTX research